德国拜耳利伐沙班用药注意事项

Germany's Bayer is the world's first highly selective oral anticoagulant that directly inhibits Factor Xa. The drug is highly selective and directly inhibits the activity of Factor Xa, thereby inhibiting the generation of thrombin and the formation of thrombus.

Headquartered in Leverkusen, Germany, Bayer has 750 production plants in 200 locations on six continents; it has 120,000 employees and 350 branches in almost every country in the world. Polymers, medicine and health care, chemical industry and agriculture are the company's four pillar industries. The company's product categories exceed 10,000 types.

Rivaroxaban is generally used for the treatment and recovery of adult patients undergoing elective hip or knee replacement surgery to prevent abnormal veins and the formation of blood clots. Rivaroxaban is an oral, bioavailable factor Xa inhibitor that selectively blocks the active site of factor Xa and does not require cofactors (such as antithrombin III) for activity. Factor X is activated into factor Xa (FXa) through endogenous and exogenous pathways, which plays an important role in the coagulation cascade.

There are precautions when taking any drug, so what are the precautions for rivaroxaban?

The indications for rivaroxaban are:

1. For use in adult patients undergoing elective hip or knee replacement surgery to prevent venous thrombosis (VTE).

2. Used to treat venous thrombosis (DVT) in adults and reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT.

3. For use in adult patients with nonvalvular atrial fibrillation who have one or more risk factors (e.g., congestive heart failure, hypertension, age ≥75 years, diabetes, history of stroke or transient ischemic attack) to reduce the risk of stroke and systemic embolism.

Precautions for rivaroxaban are:

1. Bleeding risk: As detailed below, some subgroups of patients are at higher risk of bleeding. After initiation of treatment, these patients should be monitored closely for signs of bleeding complications. This can be accomplished by regular physical examination of the patient, close observation of surgical wound drainage, and regular determination of hemoglobin. Any unexplained decrease in hemoglobin or blood pressure should prompt a search for the site of bleeding.

2. Renal damage: In patients with severe renal impairment (creatinine clearance <30 mL/min), the plasma concentration of rivaroxaban may be significantly increased, leading to an increased risk of bleeding. Rivaroxaban is not recommended for patients with creatinine clearance <15 mL/min. Rivaroxaban should be used with caution in patients with creatinine clearance 15-29 mL/min. Rivaroxaban should be used with caution in patients with moderate renal impairment (creatinine clearance 30-49 mL/min) when used concomitantly with other drugs that may increase rivaroxaban plasma concentrations.

3. Liver damage: In cirrhotic patients with moderate liver damage (Child Pugh category B), the plasma concentration of rivaroxaban may be significantly increased, leading to an increased risk of bleeding. Rivaroxaban is contraindicated in patients with liver disease associated with coagulation abnormalities and clinically relevant risk of bleeding. Rivaroxaban can be used with caution in patients with cirrhosis who have moderate hepatic impairment (Child Pugh category B) and are not accompanied by coagulation abnormalities.

4. Interactions with other drugs: in azole-antifungal agents (such as ketoconazole, itraconazole, voriconazole and posaconazole). Please read the instructions carefully and use it as directed by your doctor.

The above is the content of the precautions, I hope it can help you.

Recommended related hot articles: /newsDetail/90164.html